Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant–associated thrombotic microangiopathy?
- 15 July 2012
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 53 (3), 661-667
- https://doi.org/10.1111/j.1537-2995.2012.03776.x
Abstract
BACKGROUND: The use of therapeutic plasma exchange (TPE) in hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA‐TMA) is controversial because the exact mechanism of injury in TA‐TMA is not yet understood. STUDY DESIGN AND METHODS: The study objective was to retrospectively review the outcome of children receiving TPE for TA‐TMA at our institution. We hypothesized that patients initiating TPE earlier in their disease course would receive a greater benefit than those starting later, regardless of the therapeutic mechanism. RESULTS: We identified 10 consecutive pediatric patients with TA‐TMA treated with TPE. Nine of these patients showed normalization of the laboratory variables associated with microangiopathy during their TPE course, but only five patients recovered renal function and survived TA‐TMA. The five survivors started TPE a median of 17 days (range, 4‐25 days) after TA‐TMA diagnosis while the five patients who died started TPE a median of 32 days (range, 17‐73 days) after TA‐TMA was diagnosed. Three of the five survivors had multiorgan failure at TA‐TMA diagnosis and completely recovered with early institution of TPE. These three survivors were able to discontinue renal replacement therapy, and all achieved a normal posttreatment creatinine. The five patients with later institution of TPE progressed to end‐stage renal disease and all died. There were no serious TPE‐related complications in either group. CONCLUSION: This is the first report evaluating TPE response in regard to procedure initiation time after TA‐TMA diagnosis. Our data suggests that early initiation of TPE might be beneficial even in patients with multiorgan failure due to TA‐TMA.Keywords
This publication has 29 references indexed in Scilit:
- Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutationsPediatric Nephrology, 2011
- Validation of Recently Proposed Consensus Criteria for Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem-Cell TransplantationTransplantation, 2010
- Microangiopatias trombóticas: púrpura trombocitopênica trombótica e síndrome hemolítico-urêmicaBrazilian Journal of Nephrology, 2010
- Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCTBone Marrow Transplantation, 2010
- DEAP-HUS: Deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndromePediatric Nephrology, 2010
- Renal Thrombotic Microangiopathy after Hematopoietic Cell TransplantClinical Journal of the American Society of Nephrology, 2009
- Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximabBritish Journal of Haematology, 2007
- Rituximab Can Be Combined With Daily Plasma Exchange to Achieve Effective B-Cell Depletion and Clinical Improvement in Acute Autoimmune TTPAmerican Journal of Clinical Pathology, 2006
- Rituximab Can Be Combined With Daily Plasma Exchange to Achieve Effective B-Cell Depletion and Clinical Improvement in Acute Autoimmune TTPAmerican Journal of Clinical Pathology, 2006
- The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and AdolescentsPediatrics, 2004